#5-15E. Unveiling Epigenetic Precursors: Predicting Lymphoma Risk in Sjögren’s Disease (Arthritis Rheumatol, 2026)

How can we predict which patients with primary Sjögren’s disease will eventually develop lymphoma years before the actual diagnosis? In this episode, we explore the recent study "Peripheral blood DNA methylation changes precede lymphoma diagnosis in primary Sjögren’s disease," which analyzed pre-diagnostic peripheral blood samples to identify epigenetic alterations associated with lymphomagenesis. The researchers discovered that specific DNA methylation changes, particularly widespread hypomethylation in genes related to immune regulation, cellular proliferation, and cytotoxic function, are evident well in advance of a lymphoma diagnosis. The most striking finding is the profound hypomethylation of the TK1 gene, suggesting enhanced proliferative activity prior to overt malignant transformation, which holds immense potential as a minimally invasive biomarker for early risk stratification. However, when critically appraising this study, clinicians must interpret these findings with caution due to the very small sample size of only six pre-lymphoma cases and the considerable heterogeneity of the lymphoma subtypes included. For practicing physicians, this paper is highly relevant as it lays the groundwork for integrating molecular epigenetic profiling into our clinical toolkit, potentially transforming how we monitor and proactively manage high-risk Sjögren’s patients in the future.

Citation: Lidberg H, Fugmann C, Imgenberg-Kreuz J. Peripheral blood DNA methylation changes precede lymphoma diagnosis in primary Sjögren’s disease. Arthritis & Rheumatology. 2026. Online ahead of print.

DOI: 10.1002/art.70271

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.